Certara will announce Q3 2025 financial results on November 6, followed by a conference call at 5:00 PM ET.
Quiver AI Summary
Certara, Inc. announced that it will release its financial results for the third quarter of 2025 after the market closes on November 6, 2025. Following the release, the company will host a conference call at 5:00 PM ET to discuss the results, and interested investors must register online in advance. A live and archived webcast of the call will be available on Certara's website. Certara specializes in accelerating drug discovery and development through its biosimulation software and services, serving over 2,400 clients in 70 countries.
Potential Positives
- Certara will release its financial results for Q3 2025, indicating transparency and communication with investors.
- The scheduled conference call provides an opportunity for management to directly engage with investors, enhancing investor relations.
- Certara serves a significant number of clients (over 2,400) globally, highlighting its leadership position in the biosimulation market.
- The availability of a live and archived webcast improves accessibility for investors and stakeholders, demonstrating a commitment to inclusivity in communication.
Potential Negatives
- The press release does not provide any specific details about the anticipated financial results, which may raise concerns about transparency and investor confidence.
- Timing of the financial results release on November 6th could suggest potential issues if results are presented later than expected, which might affect market perception.
- Requiring investors to register online for the conference call may limit accessibility and participation from interested stakeholders.
FAQ
What date will Certara announce its Q3 2025 financial results?
Certara will release its financial results for the third quarter of 2025 on November 6th, 2025.
What time is the Certara Q3 2025 earnings conference call?
The conference call to discuss the financial results will begin at 5:00 PM ET.
How can I listen to the Certara conference call?
Investors must register online to listen to the conference call. It is recommended to register at least one day in advance.
Where can I find the webcast of the Certara financial results?
A live and archived webcast will be available in the "Investors" section of the Certara website.
What services does Certara provide?
Certara offers biosimulation software, technology, and services to enhance drug discovery and development for clients globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CERT Insider Trading Activity
$CERT insiders have traded $CERT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CERT stock by insiders over the last 6 months:
- LEIF E PEDERSEN (PRESIDENT, CHIEF COMMERCAL OFF) sold 51,224 shares for an estimated $559,366
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CERT Hedge Fund Activity
We have seen 111 institutional investors add shares of $CERT stock to their portfolio, and 141 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP added 4,244,230 shares (+45.7%) to their portfolio in Q2 2025, for an estimated $49,657,491
- DEERFIELD MANAGEMENT COMPANY, L.P. added 3,926,099 shares (+inf%) to their portfolio in Q2 2025, for an estimated $45,935,358
- RIVERBRIDGE PARTNERS LLC removed 2,004,778 shares (-97.9%) from their portfolio in Q2 2025, for an estimated $23,455,902
- DAVENTRY GROUP, LP removed 1,802,527 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,089,565
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 1,798,363 shares (-96.3%) from their portfolio in Q2 2025, for an estimated $21,040,847
- MARSHALL WACE, LLP added 1,413,538 shares (+1430.6%) to their portfolio in Q2 2025, for an estimated $16,538,394
- AMERIPRISE FINANCIAL INC added 1,165,064 shares (+27.1%) to their portfolio in Q2 2025, for an estimated $13,631,248
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CERT Analyst Ratings
Wall Street analysts have issued reports on $CERT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 10/08/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- Craig-Hallum issued a "Buy" rating on 09/29/2025
- UBS issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $CERT, check out Quiver Quantitative's $CERT forecast page.
$CERT Price Targets
Multiple analysts have issued price targets for $CERT recently. We have seen 5 analysts offer price targets for $CERT in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Scott Schoenhaus from Keybanc set a target price of $16.0 on 10/08/2025
- Luke Sergott from Barclays set a target price of $16.0 on 10/02/2025
- Matthew Hewitt from Craig-Hallum set a target price of $16.0 on 09/29/2025
- Dan Leonard from UBS set a target price of $15.0 on 08/07/2025
- Sean Laaman from Morgan Stanley set a target price of $16.0 on 07/03/2025
Full Release
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6 th , 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Investors interested in listening to the conference call are required to register online . It is recommended to register at least one day in advance.
A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/ .
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
[email protected]
Media Contact:
Alyssa Horowitz
[email protected]
